Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
PharmAbcine, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'PharmAbcine, Inc. - Product Pipeline Review - 2014', provides an overview of the PharmAbcine, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of PharmAbcine, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of PharmAbcine, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of PharmAbcine, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the PharmAbcine, Inc.'s pipeline products Reasons to buy - Evaluate PharmAbcine, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of PharmAbcine, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the PharmAbcine, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of PharmAbcine, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of PharmAbcine, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of PharmAbcine, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 PharmAbcine, Inc. Snapshot 5 PharmAbcine, Inc. Overview 5 Key Information 5 Key Facts 5 PharmAbcine, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 PharmAbcine, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 PharmAbcine, Inc. - Pipeline Products Glance 11 PharmAbcine, Inc. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 PharmAbcine, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 PharmAbcine, Inc. - Drug Profiles 14 TTAC-0001 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 PMC-001 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 PMC-002 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 PMC-201 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Monoclonal Antibody to Antagonize c-Met for Cancer and Inflammatory Disorders 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Monoclonal Antibody to Antagonize EGFR for Cancer and Inflammatory Disorders 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibody to Antagonize HER2 for Cancer and Inflammatory Disorders 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibody to Antagonize IGFR-1 for Cancer and Inflammatory Disorders 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibody to Antagonize VEGFR-1 for Cancer and Inflammatory Disorders 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibody to Antagonize VEGFR-3 for Cancer and Inflammatory Disorders 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibody to Inhibit DLL4 for Cancer and Inflammatory Disorders 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibody to Inhibit EPCAM for Cancer and Inflammatory Disorders 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody to Target CD-20 for Cancer and Inflammatory Disorders 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 PharmAbcine, Inc. - Pipeline Analysis 27 PharmAbcine, Inc. - Pipeline Products by Target 27 PharmAbcine, Inc. - Pipeline Products by Molecule Type 28 PharmAbcine, Inc. - Pipeline Products by Mechanism of Action 29 PharmAbcine, Inc. - Locations And Subsidiaries 31 Head Office 31 Other Locations & Subsidiaries 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables PharmAbcine, Inc., Key Information 5 PharmAbcine, Inc., Key Facts 5 PharmAbcine, Inc. - Pipeline by Indication, 2014 8 PharmAbcine, Inc. - Pipeline by Stage of Development, 2014 9 PharmAbcine, Inc. - Monotherapy Products in Pipeline, 2014 10 PharmAbcine, Inc. - Phase I, 2014 11 PharmAbcine, Inc. - Preclinical, 2014 12 PharmAbcine, Inc. - Discovery, 2014 13 PharmAbcine, Inc. - Pipeline by Target, 2014 27 PharmAbcine, Inc. - Pipeline by Molecule Type, 2014 28 PharmAbcine, Inc. - Pipeline Products by Mechanism of Action, 2014 30 PharmAbcine, Inc., Other Locations 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.